nasopharyng
carcinoma
npc
endem
southern
china
southeast
asia
longterm
surviv
patient
advanc
npc
remain
poor
despit
use
salvag
chemotherapi
molecular
target
therapi
yet
achiev
signific
benefit
npc
thu
novel
approach
urgent
need
npc
asia
almost
univers
associ
ebv
viral
oncoprotein
express
tumor
cell
immunotherapi
repres
promis
therapeut
studi
use
adopt
transfer
ebvspecif
cytotox
cell
ctl
npc
shown
clinic
respons
patient
howev
overal
efficaci
modest
especi
patient
metastat
andor
bulki
diseas
nonmyeloabl
peripher
blood
stem
cell
transplant
nst
may
present
anoth
immunotherapeut
approach
patient
advanc
stage
npc
potent
graftvstumor
gvt
nst
shown
efficaci
rang
solid
tumor
includ
renal
cell
breast
colon
role
npc
howev
yet
evalu
evalu
role
nst
patient
pretreat
metastat
npc
conduct
prospect
phase
ii
studi
use
nst
regimen
modifi
spitzer
et
use
compar
lymphodeplet
rabbit
antithymocyt
globulin
thymoglobulin
aim
induc
stabl
mix
chimer
final
convers
full
donor
lymphohematopoiet
chimera
singl
agent
cya
taper
rapidli
protocol
donor
lymphocyt
infus
use
need
although
patient
studi
heavili
pretreat
achiev
reason
respons
rate
nst
sever
patient
durabl
diseas
control
patient
year
eastern
cooper
oncolog
group
perform
statu
ps
metastat
npc
receiv
least
one
line
salvag
chemotherapi
elig
patient
left
ventricular
eject
fraction
activ
angina
pectori
uncontrol
arrhythmia
hypertens
sever
chronic
restrict
lung
diseas
correct
diffus
capac
carbon
monoxid
creatinin
clearanc
mlmin
serum
bilirubin
ml
alt
ast
upper
limit
normal
exclud
patient
activ
uncontrol
infect
activ
central
nervou
system
diseas
human
immunodefici
viru
hepat
b
c
posit
serolog
written
inform
consent
obtain
patient
studi
approv
institut
ethic
committe
nation
cancer
centr
singapor
dedic
hepafilt
bmt
room
patient
receiv
condit
regimen
iv
cy
mgkgday
day
singl
fraction
gy
thymic
irradi
unless
previou
mediastin
radiat
day
vivo
tcell
deplet
rabbit
antithymocyt
globulin
thymoglobulin
genzym
cambridg
usa
mgkgday
initi
day
regimen
schedul
later
modifi
day
regimen
secondari
graft
loss
patient
receiv
regimen
patient
receiv
unmanipul
allogen
pbsc
graft
hlaident
singl
agmismatch
sibl
donor
donor
pbmc
collect
leukapheresi
donor
leukocyt
infus
dli
consid
least
day
complet
prophylact
cya
taper
provid
acut
gvhd
andor
donor
tcell
chimer
increas
first
dli
dose
per
kg
cell
subsequ
dli
consid
monthli
increment
increas
dose
donor
chimer
analyz
weekli
use
semiquantit
pcr
analysi
full
donor
chimer
donor
cell
mononuclear
cell
popul
achiev
patient
receiv
gvhd
prophylaxi
cya
neoral
novarti
singapor
start
mgkgday
iv
divid
two
dose
day
reduc
mgkgday
engraft
patient
convert
daili
oral
cya
mgkg
aim
therapeut
trough
level
ngml
absenc
acut
gvhd
cya
rapidli
taper
prophylact
ciprofloxacin
fluconazol
acyclovir
cotrimoxazol
administ
describ
acut
gvhd
ii
methylprednisolon
mgkgday
initi
cmv
infect
screen
use
viral
antigenemia
assay
weekli
hospit
discharg
day
preemptiv
iv
ganciclovir
administ
accord
institut
practic
toxic
grade
accord
nation
cancer
institut
common
toxic
criteria
version
sever
acut
gvhd
accord
intern
bone
marrow
transplant
registri
criteria
postdli
acut
chronic
gvhd
common
peripher
blood
collect
evalu
npc
patient
prenst
serial
postnst
healthi
volunt
serv
normal
control
immunophenotyp
human
lymphocyt
perform
multicolor
flow
cytometr
analysi
facscalibur
becton
dickinson
san
jose
ca
usa
determin
level
specif
function
tcell
subset
naiv
memoryeffector
cell
regulatori
treg
dna
extract
plasma
sampl
collect
monthli
interv
realtim
pcr
ebvspecif
probe
primer
set
target
epsteinbarr
nuclear
antigen
region
perform
previous
interv
pf
calcul
date
transplant
first
document
diseas
progress
death
caus
last
followup
os
durat
date
transplant
first
document
death
caus
last
followup
durat
respons
measur
date
first
object
recist
respons
date
diseas
progress
death
whichev
earlier
time
respons
measur
date
transplant
first
document
respons
pearson
fisher
exact
test
use
test
associ
categor
variabl
wherea
utest
use
test
differ
continu
variabl
best
overal
tumor
respons
rate
summar
confid
interv
use
wilson
surviv
respons
curv
estim
method
comparison
curv
test
logrank
test
juli
juli
advanc
npc
patient
sibl
screen
hlatyp
twentysix
patient
histolog
confirm
metastat
npc
avail
hlamatch
sibl
donor
allograft
hla
oneag
mismatch
donor
allograft
accru
patient
eventu
receiv
nst
due
rapid
progress
diseas
patient
sever
acut
respiratori
syndrom
epidem
halt
accrual
patient
almost
year
median
age
year
patient
receiv
median
two
previou
chemotherapi
regimen
median
four
chemotherapi
agent
patient
extens
metastas
median
four
organ
site
previou
progress
diseas
tabl
seventeen
patient
perform
statu
ps
four
ps
median
hospit
nst
day
median
pbsc
dose
infus
pbsc
per
kg
median
time
engraft
day
three
patient
develop
mild
engraft
syndrom
ii
four
patient
secondari
engraft
loss
regimen
wherea
patient
regimen
experienc
graft
loss
one
patient
regimen
given
iv
cy
third
dli
augment
donor
chimer
patient
mix
chimer
acut
gvhd
underw
rapid
cya
taper
median
time
complet
remov
csa
evalu
patient
day
day
cya
subsequ
restart
treatment
either
acut
chronic
gvhd
patient
patient
receiv
concurr
corticosteroid
median
level
donor
chimer
among
patient
achiev
stabl
mix
chimer
day
month
postnst
sixteen
patient
receiv
dli
median
number
dli
administ
per
patient
mean
dose
administr
per
patient
cell
per
kg
immun
reconstitut
tcell
popul
postnst
outlin
supplementari
figur
treg
cell
data
provid
supplementari
figur
patient
studi
higher
baselin
treg
cell
compar
normal
control
though
differ
prenst
treg
number
respond
nonrespond
two
patient
die
within
day
transplant
one
acut
gvhd
day
patient
one
acut
pulmonari
embol
day
patient
bacteri
infect
grade
iii
iv
v
constitut
commonest
complic
occur
seven
patient
tabl
instanc
sepsi
occur
within
day
nst
effect
treat
iv
antibiot
one
patient
die
strongyloid
infect
day
postnst
one
patient
develop
cmv
retin
success
treat
ganciclovir
grade
acut
gvhd
occur
five
patient
control
standard
immunosuppress
agent
except
one
patient
die
day
follow
second
dli
chronic
gvhd
limit
diagnos
six
patient
one
patient
requir
prolong
cya
treatment
seven
patient
achiev
partial
respons
pr
three
achiev
stabl
diseas
yield
overal
respons
rate
supplementari
figur
median
time
pr
day
median
durat
pr
day
late
respons
day
observ
three
patient
patient
coincid
rise
donor
chimer
patient
gvhd
much
higher
likelihood
respons
patient
without
gvhd
figur
serial
evalu
ebv
dna
level
perform
patient
show
strong
correl
observ
clinic
respons
supplementari
tabl
time
analysi
one
patient
aliv
median
followup
day
estim
median
pf
ci
day
figur
pf
rate
se
two
patient
show
prolong
diseas
control
day
third
second
pf
day
patient
ladi
progress
lung
nodal
bone
metastas
prenst
achiev
brief
tumor
shrinkag
postnst
progress
day
follow
limit
chronic
gvhd
day
achiev
stabl
diseas
approxim
month
progress
five
dli
administ
supplementari
figur
although
diseas
continu
regress
ct
scan
object
pr
occur
much
later
day
respons
durat
day
durat
second
pf
day
patient
experienc
longest
respons
durat
day
even
though
enter
studi
extrem
aggress
diseas
evid
impend
bm
failur
prenst
symptomat
worsen
dyspnea
intens
bone
pain
despit
nsaid
opioid
analgesia
achiev
tumor
shrinkag
day
donor
chimer
increas
correl
decreas
ebv
dna
titer
figur
upon
onset
limit
chronic
gvhd
tumor
continu
shrink
regress
donor
chimer
reach
figur
one
year
nst
achiev
pr
complet
resolut
symptom
signific
improv
qualiti
life
bm
biopsi
still
posit
final
show
detect
npc
patient
achiev
chimer
week
postnst
decreas
day
attain
late
pr
day
reduct
tumor
diamet
chimer
improv
day
pr
relat
mild
ghvd
median
os
patient
underw
nst
ci
day
os
rate
se
os
rate
se
patient
chronic
gvhd
also
much
better
os
day
ci
day
vs
day
ci
day
patient
without
chronic
gvhd
figur
patient
respond
treatment
pr
stabl
diseas
also
trend
toward
better
surviv
nonrespond
median
surviv
time
ci
day
ci
day
respect
univari
respond
nonrespond
similar
age
number
diseas
site
previou
chemotherapi
although
prenst
perform
statu
poorer
respond
report
result
first
studi
explor
nst
advanc
npc
result
show
nst
feasibl
may
induc
durabl
respons
subset
patient
even
presenc
extens
bulki
diseas
studi
achiev
respons
rate
clinic
benefit
compar
well
respons
rate
achiev
second
thirdlin
chemotherapi
npc
approxim
nst
regimen
overal
well
toler
integr
thymoglobulin
atg
schedul
spitzer
regimen
result
high
incid
secondari
engraft
loss
patient
revis
incorpor
thymoglobulin
earlier
condit
timelin
regimen
may
work
better
deplet
host
donor
lymphocyt
evalu
patient
achiev
stabl
full
donor
lymphohematopoiet
chimer
studi
engraft
syndrom
occur
patient
mild
requir
treatment
compar
boston
patient
requir
highdos
steroid
control
syndrom
although
median
pf
short
pf
may
underestim
clinic
benefit
sever
reason
patient
may
experi
late
respons
occur
initi
diseas
first
event
progress
diseas
use
construct
graph
would
give
fals
impress
lack
benefit
late
respons
describ
earlier
nst
studi
occur
typic
month
post
convers
full
donor
chimer
although
may
influenc
factor
earli
withdraw
immunosuppress
use
second
patient
nst
may
experi
one
respons
exampl
patient
period
first
pf
day
second
pf
significantli
longer
day
final
nst
reconstitut
immun
system
may
chang
biolog
growth
characterist
diseas
thu
os
reliant
singl
time
point
cutoff
may
accur
measur
true
benefit
median
os
nst
studi
month
os
rate
respect
compar
median
month
os
metastat
npc
patient
importantli
subgroup
analysi
indic
chronic
gvhd
significantli
predict
respons
os
rais
question
regard
role
mha
mediat
gvt
effect
could
exploit
antitumor
despit
earli
prophylact
cya
taper
gvhd
incid
studi
accept
larg
due
high
percentag
patient
achiev
mix
chimer
day
still
infect
commonli
observ
studi
compar
nst
may
relat
xerostomia
poor
dentit
chronic
sinus
alter
mucos
barrier
npc
patient
previou
radiotherapi
primari
diseas
futur
nst
studi
consid
local
immunosuppress
featur
select
patient
nst
summari
studi
show
thymoglobulinbas
nst
induc
durabl
respons
npc
patient
overal
allow
earli
taper
prophylact
cya
accept
gvhd
rate
evid
gvt
howev
regimenrel
toxic
requir
care
patient
select
studi
nst
hodgkin
diseas
ebvrel
tumor
better
outcom
achiev
patient
induc
remiss
therefor
like
better
outcom
may
achiev
nst
perform
metastat
npc
patient
show
respons
induct
chemotherapi
